Udayavni Special

Roche’s Antibody Cocktail launched in India at Rs 59,750/dose; Cipla to market drug in country


PTI, May 24, 2021, 11:05 AM IST

New Delhi: Drug majors Roche India and Cipla on Monday announced launch of Roche’s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk.

“The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients,” Cipla and Roche said in a joint statement.

Cipla will distribute the product by leveraging its strong distribution strengths across the country, it added.

The price for each patient dose [a combined dose of 1,200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750 inclusive of all taxes. The maximum retail price for the multi dose pack (each pack can treat two patients) is Rs 1,19,500 inclusive of all taxes

As per the statement, the drug will be available through leading hospitals and COVID treatment centers.

The Central Drugs Standards Control Organisation (CDSCO) had recently provided an emergency use authorisation (EUA) for the Antibody Cocktail (Casirivimab and Imdevimab) in India. It has also received a EUA in the US and several EU countries.

“We are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimising hospitalisation, ease the burden on healthcare systems and play a key role in treatment of high risk patients before their condition worsens,” said V Simpson Emmanuel, Managing Director and CEO, Roche Pharma India.

Umang Vohra, MD and Global CEO Cipla said we look forward to leveraging our solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country.

The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe COVID-19 disease and do not require oxygen.

Vohra said it has been shown to help these high-risk patients before their condition worsens, reducing the risk of hospitalisation and fatality by 70 per cent and shortening the duration of symptoms by four days.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Delhi riots: Court defers order on ‘immediate release’ of student activists for Thursday

British PM forced to defend India travel ban timing over Delta variant in Parliament

Ambani bomb scare case: NIA seeks custody of former cop

COVID: At least half of judges should sit on alternate days to hear those in distress, says SC

No question of leadership change: Nalin Kumar Kateel

‘Two great powers’: 1st round of talks ends at Biden-Putin summit

Cong to undertake campaign to help Covid pandemic-affected people, gather data on deceased



Related Articles More

A fifth of asymptomatic covid patients develop ‘Long Covid’: study

Less than 1,000 new COVID-19 cases in Bengaluru for first time in 2 months

CSIR-IICT, Bengaluru pharma firm join hands to manufacture anti-COVID drug 2-DG

COVID-19 has created an ‘ecosystem’ of innovation in India: Kiran Mazumdar-Shaw

COVID-19: Karnataka logs 6,835 new cases, 120 deaths

MUST WATCH

Udayavani 16-JUN-2021 News Bulletin

100 % sure that I was targeted in drugs case, says Ragini Dwivedi

Baby Elephant Operates Hand Pump on Its Own to Drink Water

Suresh Shetty Gulme | Success Story of Modern Cow Dairy Farming | Kannada

Complete Guide on Mango Farming | Harvesting Techniques

Latest Additions

Delhi riots: Court defers order on ‘immediate release’ of student activists for Thursday

British PM forced to defend India travel ban timing over Delta variant in Parliament

Ambani bomb scare case: NIA seeks custody of former cop

COVID: At least half of judges should sit on alternate days to hear those in distress, says SC

No question of leadership change: Nalin Kumar Kateel

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.